Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.

A user had 4000 hair grafts in Denmark and started taking 0.5mg finasteride daily, reporting good progress after four months. The procedure cost 55,000 DKK (7,400 euros) and the user is pleased with the results, especially in the temples and crown areas.

The user is pleased with their hair growth results after using oral minoxidil (2.5mg) for 3 months and finasteride (1mg) for 4 months, despite experiencing significant shedding initially. They prefer oral treatments over topical due to convenience and concerns about toxicity to pets.

A user experienced significant hair regrowth using finasteride 1 mg daily for two years and gradually introduced dutasteride 0.5 mg daily over four months. They reported no side effects and plan to switch fully to dutasteride due to its cost-effectiveness and potential effectiveness.

Switching from 1mg finasteride to dutasteride, with users recommending starting at 0.5mg daily. Some users prefer capsules, while others use tablets, citing effectiveness and regulatory approval in Asia.

The conversation is about hair loss treatment progress using a combination of 0.1% finasteride, 0.025% tretinoin solution, and 2.5mg oral minoxidil. Users express positive reactions and hope for similar results.

A 19-year-old male using 1 mg finasteride every two days for hair loss reports no side effects and believes maintaining his current hair condition is progress. Some users see no difference in hair regrowth, attributing changes to lighting.

The user experienced significant hair regrowth after adding GHK-Cu injections to their existing treatment of topical finasteride and oral minoxidil, breaking a long plateau. They are curious if others have had similar experiences with adding new treatments to their regimen.

The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.

KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

The user started taking 0.25mg finasteride daily on 9/19/25, along with using 2% ketoconazole, rosemary oil, and dermastamping. They are hesitant to add minoxidil due to heart palpitations.

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

The user regrets not starting finasteride at 1 mg daily from the beginning, as they feel their initial microdosing was ineffective. They are now on the standard dosage and hope to see improvements in hair loss over the next few months.

A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.

A 29-year-old male experienced hair regrowth using minoxidil 5% foam and KX826 after stopping finasteride due to side effects. He applies both treatments once daily and reports no side effects from the current regimen.

The user is considering switching from topical finasteride to RU58841 or KX826 to reduce side effects but decides to stick with finasteride for now. Users discuss the effectiveness and risks of RU58841 and KX826, with finasteride being considered the most reliable option.

The conversation discusses using alfatradiol, a weaker estrogen, as a treatment for hair loss, with some users sharing their experiences and challenges in obtaining it. One user mentions using a topical solution containing alfatradiol, cetricin, caffeine, and melatonin, noting no significant hair growth but stabilization.

A 21-year-old male has been taking 1.25mg oral finasteride daily for six months and is seeking feedback on hair improvement. Users agree there is noticeable progress, with no other treatments like minoxidil or microneedling used.

Switching from daily 0.5mg dutasteride to three times a week may reduce side effects without worsening hair loss. Bloodwork showed no abnormalities, supporting the change.

Topical finasteride in a liposomal formulation reduces systemic absorption compared to ethanol solutions. The user is seeking sources for such products, noting that popular options like morr-f are not liposomal.

A user shared their 3-year progress using finasteride and minoxidil for hair loss, noting significant improvement after adding minoxidil to their routine. They also use a derma roller weekly and apply minoxidil topically to the entire hairline.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Switching from powdered dutasteride to softgel significantly reduced DHT levels, suggesting softgels are more effective due to better bioavailability. Users discuss the ineffectiveness of compounded forms and emphasize the importance of proper formulation for absorption.

User shared 9 months of progress using 1 mg finasteride and topical minoxidil, showing photos from different stages. Encouragement was given to continue the treatment.

The user has been using finasteride (1 mg, three times a week) for a year and is considering adding oral minoxidil or increasing finasteride dosage, while also taking enclomiphene. They did not experience significant shedding with finasteride, but are concerned about potential shedding with new treatments.

A 23-year-old shared positive hair regrowth results after using 1mg of oral Finasteride daily for three months, with no side effects reported. The user hopes to continue without adding Minoxidil, as Finasteride alone has been effective.

The user has been taking finasteride 1.25mg daily since February 2025, with no noticeable side effects and occasional use of keto shampoo. The treatment seems to have stabilized hair loss, with some users noting subtle regrowth and pigmentation changes.